Vistra Corp
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
9. Earnings Per Share
- EARNINGS PER SHARE
Basic earnings per share available to common stockholders are based on the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the treasury stock method and includes the effect of all potential issuances of common shares under stock-based incentive compensation arrangements. Cumulative dividends attributable to Series C Preferred Stock were immaterial during the year ended December 31, 2023.
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net income (loss) attributable to Vistra | $1,493 | $(1,227) | $(1,274) |
| Less cumulative dividends attributable to Series A Preferred Stock | (80) | (80) | (17) |
| Less cumulative dividends attributable to Series B Preferred Stock | (70) | (70) | (4) |
| Less cumulative dividends attributable to Series C Preferred Stock | — | — | — |
| Net income (loss) attributable to common stock — basic | 1,343 | (1,377) | (1,295) |
| Weighted average shares of common stock outstanding — basic | 369,771,359 | 422,447,074 | 482,214,544 |
| Net income (loss) per weighted average share of common stock outstanding — basic | $3.63 | $(3.26) | $(2.69) |
| Dilutive securities: Stock-based incentive compensation plan | 5,421,752 | — | — |
| Weighted average shares of common stock outstanding — diluted | 375,193,110 | 422,447,074 | 482,214,544 |
| Net income (loss) per weighted average share of common stock outstanding — diluted | $3.58 | $(3.26) | $(2.69) |
Stock-based incentive compensation plan awards excluded from the calculation of diluted earnings per share because the effect would have been antidilutive totaled 392,218,8,292,647 and 14,412,299 shares for the years ended December 31, 2023, 2022 and 2021, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.